Connecting Molecules to Medicine®
See What Makes Nexus Pharmaceuticals Different
Through our commitment to innovative R&D, Nexus Pharmaceuticals identifies off-patent and difficult to formulate molecules that can be developed, improved upon, and commercialized to advance industry standards and deliver on critical medical needs.
State-of-the-Art Sterile Injectable Manufacturing Facility
Located in Pleasant Prairie, Wisconsin, we broke ground in 2019 to build Project Tomorrow, a state-of-the-art sterile injectable manufacturing facility to support the production and supply of injectable drugs in various therapeutic areas including anesthesiology, oncology, cardiology, and neurology. We plan to invest $250 million over the next ten years and create over 400 jobs in total.
LINCOLNSHIRE, Ill. – Nexus Pharmaceuticals is pleased to announce its certification as a Great Place to Work by the Great Place to Work® Institute for the third consecutive year. In addition to the certification, Nexus has been recognized as #19 on the list of Best Small & Medium Workplaces in Chicago. The US-based manufacturer is the only pharmaceutical company to make the Top 20 list.
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™¥.
I am writing with regards to the Opinion piece titled, “Our Drug Supply Is Sick. How Can We Fix It?” (Sept. 18, 2021). As the writer clearly highlights, the U.S. generic pharmaceutical industry is facing a crisis. Our company, Nexus Pharmaceuticals, Inc., is leading...
Find out what we’re about
Discover more about Nexus Pharmaceuticals and get in touch today!